NCT06282536View on ClinicalTrials.gov

Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2029

Conditions
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Interventions
DRUG

Iruplinalkib

60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.

PROCEDURE

surgery

Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06282536 - Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | Biotech Hunter | Biotech Hunter